AREC - Arecor Therapeutics takes major step with first commercial sale of AT220
(NewsDirect)
Arecor Therapeutics PLC CEO Sarah Howellspeaks to Thomas Warner from Proactive after the biopharmaceuticalgroup announced the first commercial sale of a product thatincorporates its proprietary Arestat technology, known as AT220.
Part of a licence agreement with anunnamed global pharma partner initiated in 2017, the milestone hastriggered a payment to Arecor. It will also receive royalties onsales.
Howell explains thesignificance of the news, emphasising its importance for patients andthe business. She says the achievement aligns with Arecor's visionof building a large, self-sustaining biopharmaceutical company focusedon improving patient care.
Whilethe partner involved in this achievement remains undisclosed, Howellshed light on Arecor's appeal to pharmaceutical collaborators andsays the Arestat technology enables the company to enhance biosimilarproducts, providing more benefits to patients and giving partners acompetitive edge in a high-value market.
She says the financial impact is significant, with the milestonetriggering licensed payments and initiating recurring royalty streamsfor Arecor.
As the year approachesits end, Howell hints at potential updates. The partnered portfolioshows promising progress, with recent announcements of licensedmilestones and positive developments in clinical studies. Ongoingpartnerships with pharmaceutical and biotech companies are expected toexpand, contributing to Arecor's growth.
The company isactively developing its proprietary products, focusing on specialtyhospital medications and diabetes treatments. One of their leaddiabetes products, AT278, targets patients with high insulin needs,presenting a disruptive solution in a growing market segment. Resultsfrom the clinical study are anticipated in Q1 2024.
ContactDetails
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.